DK3300743T3 - Fremgangsmåder til indgivelse af vaccine - Google Patents

Fremgangsmåder til indgivelse af vaccine Download PDF

Info

Publication number
DK3300743T3
DK3300743T3 DK17202017.4T DK17202017T DK3300743T3 DK 3300743 T3 DK3300743 T3 DK 3300743T3 DK 17202017 T DK17202017 T DK 17202017T DK 3300743 T3 DK3300743 T3 DK 3300743T3
Authority
DK
Denmark
Prior art keywords
vaccine
administration
procedures
Prior art date
Application number
DK17202017.4T
Other languages
English (en)
Inventor
Cassius Mcallister Tucker
John David Haworth
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39609100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3300743(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Application granted granted Critical
Publication of DK3300743T3 publication Critical patent/DK3300743T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DK17202017.4T 2006-12-27 2007-11-23 Fremgangsmåder til indgivelse af vaccine DK3300743T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87732206P 2006-12-27 2006-12-27
EP14166489.6A EP2762163B1 (en) 2006-12-27 2007-11-23 Methods of vaccine administration

Publications (1)

Publication Number Publication Date
DK3300743T3 true DK3300743T3 (da) 2023-07-24

Family

ID=39609100

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17202017.4T DK3300743T3 (da) 2006-12-27 2007-11-23 Fremgangsmåder til indgivelse af vaccine
DK14166489.6T DK2762163T3 (da) 2006-12-27 2007-11-23 Fremgangsmåde til indgivelse af vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14166489.6T DK2762163T3 (da) 2006-12-27 2007-11-23 Fremgangsmåde til indgivelse af vaccine

Country Status (25)

Country Link
US (4) US20100028379A1 (da)
EP (5) EP2762163B1 (da)
JP (1) JP5762664B2 (da)
KR (1) KR101099883B1 (da)
CN (1) CN101573137B (da)
AR (1) AR064530A1 (da)
AU (1) AU2007343130C1 (da)
BR (1) BRPI0720667A8 (da)
CA (1) CA2674026C (da)
CY (1) CY1120015T1 (da)
DK (2) DK3300743T3 (da)
ES (2) ES2951660T3 (da)
FI (1) FI3300743T3 (da)
HK (4) HK1134243A1 (da)
HU (2) HUE062920T2 (da)
LT (1) LT2762163T (da)
MX (1) MX2009007087A (da)
NZ (1) NZ577855A (da)
PL (2) PL2762163T3 (da)
PT (1) PT2762163T (da)
SI (1) SI2762163T1 (da)
TR (1) TR201802917T4 (da)
TW (1) TW200833354A (da)
WO (1) WO2008084294A2 (da)
ZA (1) ZA200904756B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
MX2009007087A (es) * 2006-12-27 2009-08-12 Pfizer Prod Inc Metodos para la administracion de vacunas.
WO2009094006A2 (en) 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
AU2010273382A1 (en) * 2009-07-17 2012-02-02 The Board Of Regents For Oklahoma State University Supralingual vaccines and applicators
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
CN101914502B (zh) * 2010-07-30 2012-01-11 中国农业科学院哈尔滨兽医研究所 Ⅰ型犬腺病毒弱毒疫苗株及其应用
US20120107354A1 (en) * 2010-10-30 2012-05-03 George Dacai Liu Viral vaccine and process for preparing the same
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
TW201233802A (en) * 2010-12-02 2012-08-16 Oncolytics Biotech Inc Liquid viral formulations
WO2012124764A1 (ja) 2011-03-17 2012-09-20 国立大学法人三重大学 抗体の製造方法
US10632189B2 (en) * 2012-05-31 2020-04-28 Zoetis Services Llc Canine respiratory coronavirus for treatment and protection against bacterial infections
CZ307883B6 (cs) * 2013-01-29 2019-07-24 Bioveta, A.S. Multivalentní vakcína k imunoprofylaxi infekčních onemocnění psů
CN107320720A (zh) * 2016-04-29 2017-11-07 普莱柯生物工程股份有限公司 一种疫苗组合物、试剂盒及应用
CN106591242B (zh) * 2016-11-18 2019-08-30 北京世纪元亨动物防疫技术有限公司 一株犬细小病毒毒株cpv-yh及其应用
CA3053152A1 (en) * 2017-02-13 2018-08-16 Aurelie De Malibran-Santibanez Liquid applicator for delivering vaccines
GB201806460D0 (en) * 2018-04-20 2018-06-06 Secr Defence Pharmaceutical compositions and associated kits

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE3526809A1 (de) * 1985-07-26 1987-04-02 Behringwerke Ag Tollwut-lebendimpfstoff
DE3775783D1 (de) 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4990367A (en) * 1987-03-09 1991-02-05 Diamond Scientific Company Canine distemper virus vaccine
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
FR2652501B1 (fr) 1989-10-02 1992-01-10 Rhone Merieux Elements therapeutiques pour l'administration orale d'un medicament aux animaux et procede de fabrication.
US5178862A (en) * 1989-12-01 1993-01-12 Parhelion Corporation Canine distemper virus vaccine and method of preparation
US5757063A (en) * 1994-03-25 1998-05-26 Kabushiki Kaisha Toshiba Semiconductor device having an extrinsic gettering film
CN1117081A (zh) * 1995-03-16 1996-02-21 高云 犬瘟热狂犬病细小病毒三联活疫苗、毒种及制造方法
CN1137347A (zh) * 1995-06-22 1996-12-11 中国人民解放军第四军医大学 犬五联(犬狂犬、犬瘟热、犬细小病毒、犬腺病毒2型、犬副流感)活疫苗
AU4133397A (en) * 1996-10-28 1998-05-22 Pfizer Inc. Oral vaccines for young animals with an enteric coating
US5884583A (en) 1997-03-28 1999-03-23 Rhone Merieux, Inc. Field bag boost vaccination delivery system
US6867353B2 (en) 2000-02-12 2005-03-15 Exploregen Inc. Production method of recombinant rotavirus structural proteins and vaccine composition
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
US20030129161A1 (en) 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
DE602004013723D1 (de) * 2003-01-29 2008-06-26 Pfizer Prod Inc Hundeimpfstoffe gegen bordetella bronchiseptica
CA2571316A1 (en) 2004-06-21 2006-01-05 Merial Limited Vaccination of skunks and/or mongooses against rabies
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
WO2006106424A2 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
EP2452693A3 (en) * 2005-10-07 2012-06-06 Pfizer Products Inc. Vaccines and methods to treat canine influenza
MX2009007087A (es) * 2006-12-27 2009-08-12 Pfizer Prod Inc Metodos para la administracion de vacunas.

Also Published As

Publication number Publication date
BRPI0720667A2 (pt) 2014-01-14
US11524068B2 (en) 2022-12-13
ES2660035T3 (es) 2018-03-20
EP3300743A1 (en) 2018-04-04
FI3300743T3 (fi) 2023-08-11
CA2674026A1 (en) 2008-07-17
CN101573137B (zh) 2014-05-14
KR20090094393A (ko) 2009-09-04
HK1200372A1 (en) 2015-08-07
ES2951660T3 (es) 2023-10-24
HK1134243A1 (en) 2010-04-23
CA2674026C (en) 2018-08-21
HK1249031A1 (zh) 2018-10-26
EP4233899A2 (en) 2023-08-30
AU2007343130A1 (en) 2008-07-17
US11524067B2 (en) 2022-12-13
HUE036174T2 (hu) 2018-06-28
AU2007343130B2 (en) 2012-12-20
AU2007343130C1 (en) 2017-11-09
EP2762163A1 (en) 2014-08-06
EP2129392B1 (en) 2013-07-31
WO2008084294A2 (en) 2008-07-17
EP2762163B1 (en) 2018-01-03
LT2762163T (lt) 2018-02-26
HK1200374A1 (en) 2015-08-07
CY1120015T1 (el) 2018-12-12
CN101573137A (zh) 2009-11-04
US20100028379A1 (en) 2010-02-04
TR201802917T4 (tr) 2018-03-21
SI2762163T1 (en) 2018-05-31
NZ577855A (en) 2012-07-27
US20230078668A1 (en) 2023-03-16
JP5762664B2 (ja) 2015-08-12
TW200833354A (en) 2008-08-16
AR064530A1 (es) 2009-04-08
DK2762163T3 (da) 2018-02-12
US20150182619A1 (en) 2015-07-02
EP3300743B1 (en) 2023-06-14
ZA200904756B (en) 2010-05-26
PT2762163T (pt) 2018-02-22
US20200316192A1 (en) 2020-10-08
PL3300743T3 (pl) 2023-09-11
MX2009007087A (es) 2009-08-12
BRPI0720667A8 (pt) 2017-04-25
JP2008169207A (ja) 2008-07-24
HUE062920T2 (hu) 2023-12-28
EP4233899A3 (en) 2023-11-08
KR101099883B1 (ko) 2011-12-28
PL2762163T3 (pl) 2018-05-30
EP2129392A2 (en) 2009-12-09
EP2762162A1 (en) 2014-08-06
WO2008084294A3 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2152290T3 (da) Fremgangsmåder til indgivelse af anti-il-5-antistoffer
DK2173407T3 (da) Anordning til indgivelse af lægemiddel
DK2107917T3 (da) Injektionssted til injektion af lægemiddel
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
DK2054073T3 (da) Farmaceutiske præparater til fremføring med langvarig frigivelse af peptider
DK2231565T3 (da) Fremgangsmåder til fremstilling af clorerede carbonhydrider
ATE450271T1 (de) Impfstoff
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
DK2048941T3 (da) Fremgangsmåde til opdræt af rovmider
DK1981863T3 (da) Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK1981859T3 (da) Fremstilling af delmopinol
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK3192500T3 (da) Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere
DK2114993T3 (da) Vaccine
BRPI0718548A2 (pt) Estabilização de vacinas por liofilização
DK2043682T3 (da) Influenzavaccine
DK3005986T3 (da) Infusion af lægemidler
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
BRPI0719394A2 (pt) Preparação medicinal sólida
DK2121553T3 (da) Fremgangsmåde til fremstillingen af terapeutisk værdi-fulde triphenylbutenderivater